Dissenting Views
[To accompany H.R. 1691]
[Including cost estimate of the Congressional Budget Office]
The Committee on Ways and Means, to whom was referred the
bill (H.R. 1691) to amend title XVIII of the Social Security
Act to ensure prompt coverage of breakthrough devices under the
Medicare program, and for other purposes, having considered the
same, reports favorably thereon with an amendment and
recommends that the bill as amended do pass.
CONTENTS
Page
I. SUMMARY AND BACKGROUND...........................................3
A. Purpose and Summary................................. 3
B. Background and Need for Legislation................. 3
C. Legislative History................................. 4
Background......................................... 4
Committee Hearings................................. 4
Committee Action................................... 4
D. Designated Hearing.................................. 4
II. EXPLANATION OF THE BILL..........................................4
A. Reasons for Change.................................. 4
B. Explanation of Provisions........................... 5
C. Effective Date...................................... 5
III. VOTES OF THE COMMITTEE...........................................5
IV. BUDGET EFFECTS OF THE BILL.......................................6
A. Committee Estimate of Budgetary Effects............. 6
B. Statement Regarding New Budget Authority and Tax
Expenditures Budget Authority...................... 6
C. Cost Estimate Prepared by the Congressional Budget
Office............................................. 6
V. OTHER MATTERS TO BE DISCUSSED UNDER THE RULES OF THE HOUSE.......8
A. Committee Oversight Findings and Recommendations.... 8
B. Statement of General Performance Goals and
Objectives......................................... 8
C. Information Relating to Unfunded Mandates........... 8
D. Congressional Earmarks, Limited Tax Benefits, and
Limited Tariff Benefits............................ 9
E. Duplication of Federal Programs..................... 9
VI. CHANGES IN EXISTING LAW MADE BY THE BILL, AS REPORTED............9
VII. DISSENTING VIEWS...............................................102
The amendment is as follows:
Strike all after the enacting clause and insert the
following:
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Ensuring Patient Access to Critical
Breakthrough Products Act of 2024''.
SEC. 2. ENSURING PROMPT COVERAGE OF BREAKTHROUGH DEVICES UNDER THE
MEDICARE PROGRAM.
(a) Ensuring Coverage Through a Transitional Coverage Period.--
(1) In general.--Section 1862(a)(1) of the Social Security
Act (42 U.S.C. 1395y(a)(1)) is amended--
(A) in subparagraph (O), by striking ``and'' at the
end;
(B) in subparagraph (P), by adding ``and'' at the
end; and
(C) by inserting after subparagraph (P) the following
new subparagraph:
``(Q) in the case of a breakthrough device (as defined in
section 1861(nnn)) furnished during the transitional coverage
period (as so defined) with respect to such device, which is
not furnished in accordance with the Food and Drug
Administration-approved labeling for such device or that the
Secretary determines, based on a review of clinical data,
presents an undue risk of harm that outweighs the potential
clinical benefits for individuals entitled to benefits under
part A or enrolled under part B;''.
(2) Definitions.--Section 1861 of the Social Security Act (42
U.S.C. 1395x) is amended by adding at the end the following new
subsection:
``(nnn) Breakthrough Device.--
``(1) In general.--The term `breakthrough device' means a
device so designated by the Secretary under section 1899C.
``(2) Transitional coverage period.--The term `transitional
coverage period' means, with respect to a breakthrough device,
the 4-year period that begins on the date that such device is
so designated by the Secretary under section 1899C.''.
(3) Breakthrough device determinations.--Part E of title
XVIII of the Social Security Act (42 U.S.C. 1395x et seq.) is
amended by adding at the end the following new section:
``SEC. 1899C. DESIGNATION OF BREAKTHROUGH DEVICES.
``(a) In General.--Beginning 18 months after the date of the
enactment of this section, upon application of a manufacturer of a
device (as defined in section 201 of the Federal Food, Drug, and
Cosmetic Act) that is cleared, classified, or approved under section
510(k), 513(f)(2), or 515 of such Act on or after the date of the
enactment of this section, the Secretary shall designate such device as
a breakthrough device if the Secretary determines that such device
meets the criteria specified in subsection (b).
``(b) Criteria.--For purposes of subsection (a), the criteria
specified in this subsection are, with respect to a device, the
following:
``(1) The device is provided with priority review pursuant to
section 515B of the Federal Food, Drug, and Cosmetic Act.
``(2) In the case such device is cleared under section 510(k)
of such Act, such device is so cleared based on clinical trial
information from an applicable device clinical trial (as such
terms are defined in section 402(j) of such Act) that enrolled
individuals entitled to benefits under part A or enrolled under
part B.
``(3) The device is not a clinical diagnostic laboratory
test.
``(c) Determination Process.--
``(1) In general.--The Secretary shall make a determination
with respect to a device that is the subject of an application
described in subsection (a) not later than 6 months after such
application is submitted to the Secretary.
``(2) Explanation required in case of determination that
device does not meet criteria for designation.--In the case
that the Secretary determines that a device that is the subject
of an application described in subsection (a) does not meet the
criteria specified in subsection (b), the Secretary shall
notify the manufacturer of such device of such determination
and include in such notification an explanation identifying the
specific criterion or criteria that such device failed to meet.
``(d) Reports.--The Secretary shall submit to Congress on an annual
basis a report specifying--
``(1) the number of applications received under this section
during such year;
``(2) the number of devices designated as breakthrough
devices under this section during such year; and
``(3) the number of applications for a designation for a
device under this section with respect to which the Secretary
determined that such device did not meet the criteria specified
in subsection (b) during such year.''.
(b) Ensuring Issuance of National Coverage Determination During
Transition Period.--Section 1862(l)(2) of the Social Security Act (42
U.S.C. 1395y(l)(2)) is amended by adding at the end the following new
flush sentence:
``In the case of a request for a national coverage
determination with respect to a breakthrough device (as defined
in section 1861(nnn)), the Secretary shall ensure that a final
decision is made on such request prior to the end of the
transitional coverage period (as so defined) for such device if
such request was submitted to the Secretary before the date
that is 9 months (or 12 months, in the case such request is a
request to which subparagraph (B) applies) before the last day
of such period.''.
(c) Funding.--In addition to amounts otherwise available, there are
appropriated to the Centers for Medicare & Medicaid Services Program
Management Account, out of any monies in the Treasury not otherwise
appropriated, $10,000,000 for each of fiscal years 2025 through 2030,
to remain available until expended, to carry out the amendments made by
this section.
I. SUMMARY AND BACKGROUND
A. Purpose and Summary
The purpose of this bill is to provide expedited Medicare
coverage of certain Food and Drug Administration (FDA) approved
devices as part of the Breakthrough Devices Program. The bill
would require the Centers for Medicare and Medicaid Services
(CMS) to evaluate applications for a four-year transitional
coverage period for certain medical devices approved as part of
the Breakthrough Devices Program.
B. Background and Need for Legislation
In 2016, the 21st Century Cures Act created a new pathway
for ``breakthrough'' medical devices to receive expedited FDA
approval. According to the FDA website, the Breakthrough
Devices Program is intended to ``provide patients and health
care providers with timely access to medical devices by
speeding up development, assessment, and review for premarket
approval, 510(k) clearance, and De Novo marketing
authorization. Breakthrough Devices must meet the FDA's
rigorous standards for device safety and effectiveness in order
to be authorized for marketing.''
The criteria to be eligible for the Breakthrough Devices
Program is the device must first provide for more effective
treatment or diagnosis of life-threatening or irreversibly
debilitating human disease or conditions and second meet one of
the following criteria--represent breakthrough technology, have
no approved or cleared alternative, offer a significant
advantage over existing approved or cleared alternatives, or
the availability of the device is in the best interest of
patients.
Unfortunately, at the time Congress passed the 21st Century
Cures Act, Congress did not create a corresponding pathway for
coverage at CMS. This means the 95 devices that have received
approval under the Breakthrough Devices Program as of December
31, 2023 were not assured of coverage under the Medicare
program--denying seniors access to materially better
treatments. According to the Stanford Byers Center for
Biodesign, it takes Medicare over five years on average to
provide coverage for a breakthrough device.
The lack of companion Medicare coverage pathway for
Breakthrough Devices is needlessly denying seniors access to
innovative medical treatments. It is essential for Congress to
provide a pathway for transitional coverage for these devices
within Medicare.
C. Legislative History
Committee Action
The Committee on Ways and Means marked up H.R. 1691, the
Ensuring Patient Access to Critical Breakthrough Products Act,
on June 27, 2024, and favorably reported the bill, as amended,
to the House of Representatives (with quorum being present).
D. Designated Hearing
Pursuant to clause 3(c)(6) of rule XIII, the following
hearing was used to develop and consider H.R. 1691:
``Examining Policies that Inhibit Innovation and Patient
Access'' on May 10, 2023.
II. EXPLANATION OF THE BILL
A. Reasons for Change
The Committee on Ways and Means' reason for change is to
solve the underlying problem of long waits between FDA approval
of Breakthrough Devices and their coverage under Medicare.
B. Explanation of Provisions
Section 1. Short title.
The short title is ``Ensuring Patient Access to Critical
Breakthrough Products Act of 2024''.
Section 2. Ensuring Prompt Coverage of Breakthrough Devices Under the
Medicare Program.
This provision provides a distinct pathway for four years
of transitional Medicare coverage of certain FDA approved
breakthrough medical devices and requires the Centers for
Medicare and Medicaid Services (CMS) to make a permanent
coverage determination by the end of the coverage period if so
requested.
C. Effective Date
The bill would become effective 18 months after the date of
enactment.
III. VOTES OF THE COMMITTEE
In compliance with the Rules of the House of
Representatives, the following statement is made concerning the
vote of the Committee on Ways and Means during the markup
consideration of H.R. 1691, the ``Ensuring Patient Access to
Critical Breakthrough Products Act of 2023,'' on June 27, 2024.
H.R. 1691 was ordered favorably reported to the House of
Representatives as amended by a roll call vote of 36 yeas to 5
nays (with a quorum being present). The vote was as follows:
----------------------------------------------------------------------------------------------------------------
Representative Yea Nay Present Representative Yea Nay Present
----------------------------------------------------------------------------------------------------------------
Mr. Smith (MO)..................... X ...... ......... Mr. Neal............. ...... X .........
Mr. Buchanan....................... X ...... ......... Mr. Doggett.......... ...... X .........
Mr. Smith (NE)..................... X ...... ......... Mr. Thompson......... X ...... .........
Mr. Kelly.......................... X ...... ......... Mr. Larson........... ...... X .........
Mr. Schweikert..................... X ...... ......... Mr. Blumenauer....... X ...... .........
Mr. LaHood......................... X ...... ......... Mr. Pascrell......... ...... X .........
Dr. Wenstrup....................... X ...... ......... Mr. Davis............ X ...... .........
Mr. Arrington...................... X ...... ......... Ms. Sanchez.......... X ...... .........
Dr. Ferguson....................... X ...... ......... Ms. Sewell........... X ...... .........
Mr. Estes.......................... X ...... ......... Ms. DelBene.......... X ...... .........
Mr. Smucker........................ X ...... ......... Ms. Chu.............. ...... X .........
Mr. Hern........................... X ...... ......... Ms. Moore............ X ...... .........
Ms. Miller......................... X ...... ......... Mr. Kildee........... X ...... .........
Dr. Murphy......................... ...... ...... ......... Mr. Beyer............ X ...... .........
Mr. Kustoff........................ X ...... ......... Mr. Evans............ ...... ...... .........
Mr. Fitzpatrick.................... X ...... ......... Mr. Schneider........ X ...... .........
Mr. Steube......................... X ...... ......... Mr. Panetta.......... X ...... .........
Ms. Tenney......................... X ...... ......... Mr. Gomez............ X ...... .........
Mrs. Fischbach..................... X ...... .........
Mr. Moore.......................... X ...... .........
Mrs. Steel......................... X ...... .........
Ms. Van Duyne...................... X ...... .........
Mr. Feenstra....................... X ...... .........
Ms. Malliotakis.................... X ...... .........
Mr. Carey.......................... X ...... .........
----------------------------------------------------------------------------------------------------------------
IV. BUDGET EFFECTS OF THE BILL
A. Committee Estimate of Budgetary Effects
With respect to clause 3(d) of rule XIII of the Rules of
the House of Representatives, the following statement is made
concerning the effects on the budget of the bill, H.R. 1691, as
reported. The estimate prepared by the Congressional Budget
Office is included below.
B. Statement Regarding New Budget Authority and
Tax Expenditures Budget Authority
In compliance with clause 3(c)(2) of rule XIII of the Rules
of the House of Representatives, the Committee states that the
bill involved no new or increased budget authority. The
Committee states further that the bill involves no new or
increased tax expenditures.
C. Cost Estimate Prepared by the
Congressional Budget Office
In compliance with clause 3(c)(3) of rule XIII of the Rules
of the House of Representatives, requiring a cost estimate
prepared by the CBO, the following statement by CBO is
provided.
The bill would:
Require Medicare to automatically cover
certain medical devices for a four-year period
following approval from the Food and Drug
Administration (FDA)
Estimated budgetary effects would mainly stem from:
Increases in new technology add-on payments
(NTAPs) to hospitals for medical devices that would not
otherwise have been covered by Medicare
The shorter period between FDA approval of a
device and NTAPs made to hospitals
Increases in payments to Medicare Advantage
plans
Areas of significant uncertainty include:
The number and cost of medical devices
likely to be approved by the FDA and eligible for
automatic coverage
Bill summary: H.R. 1691 would require Medicare to
automatically cover devices approved under the Breakthrough
Devices Program of the Food and Drug Administration (FDA). That
program is directed at simplifying the approval process for
devices used in the treatment of especially severe diseases and
conditions. Under the bill, Medicare would be required to cover
devices within four years of FDA approval.
Estimated Federal cost: The estimated budgetary effect of
H.R. 1691 is shown in Table 1. The costs of the legislation
fall within budget function 570 (Medicare).
TABLE 1.--ESTIMATED BUDGETARY EFFECTS OF H.R. 1691
--------------------------------------------------------------------------------------------------------------------------------------------------------
By fiscal year, millions of dollars--
-----------------------------------------------------------------------------------------------------
2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2025-2029 2025-2034
--------------------------------------------------------------------------------------------------------------------------------------------------------
INCREASES OR DECREASES (-) IN DIRECT SPENDING
Estimated Budget Authority........................ 10 10 38 84 99 118 125 144 175 191 241 994
Estimated Outlays................................. 5 8 38 84 99 118 131 145 175 191 234 994
--------------------------------------------------------------------------------------------------------------------------------------------------------
Basis of estimate: For this estimate, CBO assumes that H.R.
1691 will be enacted early in fiscal year 2025.
The Medicare program does not automatically cover the use
of every medical device approved by the FDA; Medicare conducts
its own evaluations--reviews that can delay or prevent payments
to hospitals that use the devices in treating beneficiaries.
CBO expects that enacting H.R. 1691 would lead Medicare to
cover more FDA-approved breakthrough devices and that the
program's payments to hospitals would increase as a result. In
particular, spending would rise for new technology add-on
payments (NTAPs), which supplement Medicare's payments to
hospitals for treatments that have been identified as novel,
effective, and costly.
CBO estimates that under current law, over the 2027-2034
period, NTAPs will amount to $1.6 billion for roughly 120
breakthrough devices, at a cost of about $13 million per
device. (Because devices typically can qualify for NTAPs for
multiple years, the annual payment per device will be less than
$13 million.)
Direct spending: Based on analyses of the rate and timing
of NTAPs for breakthrough devices, CBO expects that enacting
H.R. 1691 would increase by roughly 25 percent the number of
devices that would be covered by Medicare and eligible for
NTAPs. As a result, over the 2025-2034 period, fee-for-service
spending would increase by about $409 million for Medicare and
by $525 million for Medicare Advantage plans.
H.R. 1691 also would appropriate $10 million each year
between 2025 and 2030 to cover the administrative costs of
implementing the bill. Based on the cost of similar activities,
CBO estimates the appropriations would cost $60 million over
the 2025-2034 period.
In total, CBO estimates that enacting H.R. 1691 would
increase direct spending by $994 million over the 2025-2034
period (see Table 1).
Uncertainty: CBO's estimate for H.R. 1691 is subject to
considerable uncertainty. The FDA's pace of device approvals
has accelerated in the recent past. According to data from the
agency, more than twice as many devices were approved between
2021 and 2023 than were approved between 2018 and 2020.\1\
Although this estimate is based on the number of currently
approved breakthrough devices, it is difficult to predict how
many FDA will approve over the next few years or what Medicare
would spend on their coverage.
---------------------------------------------------------------------------
\1\Food and Drug Administration, ``Breakthrough Devices Program''
(March 2024), https://tinyurl.com/55zyyvs8.
---------------------------------------------------------------------------
Pay-As-You-Go considerations: The Statutory Pay-As-You-Go
Act of 2010 establishes budget-reporting and enforcement
procedures for legislation affecting direct spending or
revenues. The net changes in outlays that are subject to those
pay-as-you-go procedures are shown in Table 1.
Increase in long-term net direct spending and deficits: CBO
estimates that enacting H.R. 1691 would increase net direct
spending by more than $2.5 billion in any of the four
consecutive 10-year periods beginning in 2035.
CBO estimates that enacting H.R. 1691 would increase on-
budget deficits by more than $5 billion in any of the four
consecutive 10-year periods beginning in 2035.
Mandates: The bill contains no intergovernmental or
private-sector mandates as defined in the Unfunded Mandates
Reform Act.
Estimate prepared by: Federal costs: Sarah Sajewski;
Mandates: Brandon Lever.
Estimate reviewed by: Asha Saavoss, Chief, Health Systems
and Medicare Cost Estimates Unit; Kathleen FitzGerald, Chief,
Public and Private Mandates Unit; Chad Chirico, Director of
Budget Analysis.
Estimate approved by: Phillip L. Swagel, Director,
Congressional Budget Office.
V. OTHER MATTERS TO BE DISCUSSED UNDER THE RULES OF THE HOUSE
A. Committee Oversight Findings and Recommendations
With respect to clause 3(c)(1) of rule XIII of the Rules of
the House of Representatives, the Committee made findings and
recommendations that are reflected in this report.
B. Statement of General Performance Goals and Objectives
With respect to clause 3(c)(4) of rule XIII of the Rules of
the House of Representatives, the Committee advises that the
bill does not authority funding, so no statement of general
performance goals and objectives is required.
C. Information Relating to Unfunded Mandates
This information is provided in accordance with section 423
of the Unfunded Mandates Reform Act of 1995 (Pub. L. No. 104-
4).
The Committee has determined that the bill does not contain
Federal mandates on the private sector. The Committee has
determined that the bill does not impose a Federal
intergovernmental mandate on State, local, or tribal
governments.
D. Congressional Earmarks, Limited Tax Benefits,
and Limited Tariff Benefits
With respect to clause 9 of rule XXI of the Rules of the
House of Representatives, the Committee has carefully reviewed
the provisions of the bill, and states that the provisions of
the bill do not contain any congressional earmarks, limited tax
benefits, or limited tariff benefits within the meaning of the
rule.
E. Duplication of Federal Programs
In compliance with clause 3(c)(5) of rule XIII of the Rules
of the House of Representatives, the Committee states that no
provision of the bill establishes or reauthorizes: (1) a
program of the Federal Government known to be duplicative of
another Federal program; (2) a program included in any report
from the Government Accountability Office to Congress pursuant
to section 21 of Public Law 111-139; or (3) a program related
to a program identified in the most recent Catalog of Federal
Domestic Assistance, published pursuant to the Federal Program
Information Act (Pub. L. No. 95-220, as amended by Pub. L. No.
98-169).
VI. CHANGES IN EXISTING LAW MADE BY THE BILL,
AS REPORTED
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as follows.
Changes in Existing Law Made by the Bill, as Reported
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as follows (existing law
proposed to be omitted is enclosed in black brackets, new
matter is printed in italics, and existing law in which no
change is proposed is shown in roman):
SOCIAL SECURITY ACT
* * * * * * *
TITLE XVIII--HEALTH INSURANCE FOR THE AGED AND DISABLED
* * * * * * *
Part E--Miscellaneous Provisions
definitions of services, institutions, etc.
Sec. 1861. For purposes of this title--
Spell of Illness
(a) The term ``spell of illness'' with respect to any
individual means a period of consecutive days--
(1) beginning with the first day (not included in a
previous spell of illness) (A) on which such individual
is furnished inpatient hospital services, inpatient
critical access hospital services or extended care
services, and (B) which occurs in a month for which he
is entitled to benefits under part A, and
(2) ending with the close of the first period of 60
consecutive days thereafter on each of which he is
neither an inpatient of a hospital or critical access
hospital nor an inpatient of a facility described in
section 1819(a)(1) or subsection (y)(1).
Inpatient Hospital Services
(b) The term ``inpatient hospital services'' means the
following items and services furnished to an inpatient of a
hospital and (except as provided in paragraph (3)) by the
hospital--
(1) bed and board;
(2) such nursing services and other related services,
such use of hospital facilities, and such medical
social services as are ordinarily furnished by the
hospital for the care and treatment of inpatients, and
such drugs, biologicals, supplies, appliances, and
equipment, for use in the hospital, as are ordinarily
furnished by such hospital for the care and treatment
of inpatients; and
(3) such other diagnostic or therapeutic items or
services, furnished by the hospital or by others under
arrangements with them made by the hospital, as are
ordinarily furnished to inpatients either by such
hospital or by others under such arrangements;
excluding, however--
(4) medical or surgical services provided by a
physician, resident, or intern, services described by
subsection (s)(2)(K), certified nurse-midwife services,
qualified psychologist services, and services of a
certified registered nurse anesthetist; and
(5) the services of a private-duty nurse or other
private-duty attendant.
Paragraph (4) shall not apply to services provided in a
hospital by--
(6) an intern or a resident-in-training under a
teaching program approved by the Council on Medical
Education of the American Medical Association or, in
the case of an osteopathic hospital, approved by the
Committee on Hospitals of the Bureau of Professional
Education of the American Osteopathic Association, or,
in the case of services in a hospital or osteopathic
hospital by an intern or resident-in-training in the
field of dentistry, approved by the Council on Dental
Education of the American Dental Association, or in the
case of services in a hospital or osteopathic hospital
by an intern or resident-in-training in the field of
podiatry, approved by the Council on Podiatric Medical
Education of the American Podiatric Medical
Association; or
(7) a physician where the hospital has a teaching
program approved as specified in paragraph (6), if (A)
the hospital elects to receive any payment due under
this title for reasonable costs of such services, and
(B) all physicians in such hospital agree not to bill
charges for professional services rendered in such
hospital to individuals covered under the insurance
program established by this title.
Inpatient Psychiatric Hospital Services
(c) The term ``inpatient psychiatric hospital services''
means inpatient hospital services furnished to an inpatient of
a psychiatric hospital.
Supplier
(d) The term ``supplier'
Dissenting Views
There are more than 67 million Americans on Medicare, and
they deserve timely access to medical innovations that can
meaningfully improve and extend their lives. But right now,
patients face multi-year delays even after these breakthrough
devices are deemed safe and effective by the FDA. According to
the Stanford University Byers Center for Bio-design, it takes a
median time of over 5 years after the FDA approves or clears
these devices for Medicare to cover them. These delays can have
profound consequences for patients.
For example, a novel medical device called Optune received
FDA approval in 2011 to treat glioblastoma, one of the most
deadly and difficult to treat brain cancers that more than
10,000 Americans are diagnosed with every year. Medicare did
not cover this treatment until 2019--eight years after being
deemed safe and effective by the FDA and years after all major
private health plans covered it. That same study from Stanford
found that the only statistically significant factor in
predicting how long CMS takes to approve a novel device is not
the strength of the clinical evidence, but the size of the
company that manufactures the device.
So, if a company has more money and manpower to devote to
this bureaucratic coverage process, they tend to get their
products covered faster. This harms smaller innovators while
seniors pay the price. If you or your loved one is on Medicare,
you should not be forced to use less effective treatments, or
experience delays in lifesaving care, because Medicare is
dragging its feet on covering a more effective FDA-approved
product. We can do better.
That's why I introduced bipartisan legislation with Reps.
Wenstrup, Sewell, Moore, Cardenas, and Bilirakis, as well as
Energy and Commerce Health Subcommittee Chairman Guthrie and
Ranking Member Eshoo, to speed up coverage and increase access
for seniors. The breakthrough designation was first created by
Congress in 2015 under the bipartisan 21st Century Cures Act to
speed up FDA review. Versions of our bill to speed up Medicare
review have been introduced since 2016 when it was first
sponsored by Rep. Boustany and Ranking Member Neal. I thank the
Ranking Member, Chairman, and their staffs for continuing to
improve this bill, which now has 86 bipartisan cosponsors and
was marked up with strong support in the Energy & Commerce
Committee last November.
Here are just some of the improvements made to the bill:
First, by tightening the criteria for what breakthrough
devices are eligible, we have reduced the estimated cost of
this legislation by more than 75 percent.
Second, the bill has strong safety standards, requires all
devices to be deemed safe and effective by FDA, and empowers
CMS with the ability to block coverage if there are potential
other harms.
Third, the bill requires all devices to provide sufficient
clinical trial data that includes patients from the Medicare
population to confirm these products are safe and effective.
And fourth, the bill provides $10 million per year for the
next six years for CMS to build out this new program.
I want to remind my colleagues: to receive a breakthrough
designation by the FDA, a device must provide more effective
treatment or diagnosis of life-threatening or debilitating
diseases, have no approved alternatives, or offer significant
advantages over existing options. These are not just any run-
of-the-mill medical devices. These include novel devices that
can significantly reduce bleeding complications during open
heart surgeries, diagnose skin cancer in real time, ease
tremors and stiffness for patients with Parkinson's disease,
and significantly decrease blood sugar levels.
Through 2023, out of the 933 devices that have received
breakthrough designation by the FDA over the past decade, fewer
than 100 have actually been approved by the FDA. So, we are
talking about a very limited group of groundbreaking devices
that can really improve the lives of seniors in Washington
state and across the country.
And let's also keep in mind that Medicare does eventually
cover these devices. It just takes many years. And while
seniors wait, they are forced to pay exorbitant out of pocket
costs for these life-saving devices or are denied access to
them altogether. Let's think about that for a second.
I urge my colleagues to vote yes on this important
legislation.
Suzan K. DelBene.
[all]